• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Gilead Helps Launch Türkiye's First HIV Testing Week

    3/19/24 9:16:25 AM ET
    $GILD
    $TUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GILD alert in real time by email

    Gilead Sciences:

    In the summer of 2019, Bora was celebrating his mother's birthday at a seaside restaurant in Istanbul when he suddenly became very ill and couldn't finish his meal.

    "I woke up the next day with a high fever and terrible pain and was unable to move or eat for 10 days," recalls Bora.

    It was at this point that a friend took him to an anonymous HIV testing clinic. After losing a close friend to an HIV-related condition years earlier, Bora understood the importance of taking precautions and periodically got tested.

    "I was stunned to get a positive test result, but after the initial shock I knew that with the therapies available today I would be able to manage it," Bora says.

    He immediately went on antiretroviral treatment and soon thereafter, the virus was no longer detected in his system.

    An actor and singer by profession, Bora has since also become a peer counselor with Pozitif-iz Association - a nonprofit HIV advocacy group in Istanbul. "I want people to know the importance of testing and how early detection is key to recovery and moving forward to living a healthier life," he says.

    Last fall, Bora decided to share his story more broadly with the media as Türkiye joined European HIV Testing Week for the first time since the biannual testing campaign began a decade earlier throughout the continent. During that time, Türkiye experienced a fourfold increase in HIV diagnoses over an 11-year period.

    Gilead subsequently worked closely with Pozitif-iz Association and various other partners and healthcare organizations to help launch the inaugural testing week campaign in Türkiye. As the largest private funder of nonprofit HIV programs in the U.S. and the world, Gilead strives to address unmet needs and help ensure people receive the HIV care and services they need.

    "More than 27,000 free, anonymous tests have been provided to healthcare organizations by Gilead," says Çiğdem Şimsek, founder of Pozitif-iz Association. Those diagnosed with HIV were referred for antiretroviral treatment, which is reimbursed under the national health care system.

    According to the government's figures, more than 40,000 people are now living with HIV in Türkiye, a figure Çiğdem attributes to a climate of stigma, fear, misinformation and lack of awareness and education. Young people, she says, don't have sufficient access to sex and reproductive health education in the schools so they don't know how to protect themselves against sexually transmitted diseases like HIV.

    A recent modeling study by Assistant Professor Emine Yaylali of Istanbul Technical University projects that the numbers of people living with HIV could swell to 2.4 million people by 2040 if the trend continues.

    "These are dramatic numbers, especially if you consider we're a nation of some 80 million people," says Çiğdem. "There's an urgent need to increase testing centers and build awareness in key groups." Due to this urgency, Türkiye plans to participate in the HIV testing weeks held twice a year, with the next one taking place in May.

    Bora does his part to respond to the need by answering calls that come in through the peer counseling hotline. Many of the more than 5,000 calls fielded by Pozitif-iz Association last year were from people who are afraid that they will be spurned by a spouse, family member or a friend if they are diagnosed.

    "They shouldn't despair and live in fear," he says. "I'm in a good position to tell them HIV is no longer a death sentence. Instead, it can be very manageable if detected and treated early."

    Get the next $GILD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GILD
    $TUR

    CompanyDatePrice TargetRatingAnalyst
    Gilead Sciences Inc.
    $GILD
    3/10/2026$180.00Buy
    Jefferies
    Gilead Sciences Inc.
    $GILD
    2/20/2026$155.00Equal Weight
    Barclays
    Gilead Sciences Inc.
    $GILD
    2/11/2026$140.00 → $170.00Buy
    Needham
    Gilead Sciences Inc.
    $GILD
    1/7/2026$145.00Buy
    UBS
    Gilead Sciences Inc.
    $GILD
    11/24/2025$140.00Buy
    Truist
    Gilead Sciences Inc.
    $GILD
    11/13/2025$140.00Sector Outperform
    Scotiabank
    Gilead Sciences Inc.
    $GILD
    8/19/2025$128.00Neutral → Outperform
    Daiwa Securities
    Gilead Sciences Inc.
    $GILD
    8/8/2025$127.00Hold → Buy
    Truist
    More analyst ratings

    $GILD
    $TUR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Gilead Sciences, Inc. converted options into 3,216,119 shares and bought $20,020,000 worth of shares (910,000 units at $22.00) (SEC Form 4)

    4 - GILEAD SCIENCES, INC. (0000882095) (Reporting)

    2/13/24 5:48:49 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    $TUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Dickinson Andrew D

    4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

    4/16/26 6:41:54 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Mercier Johanna

    4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

    4/16/26 6:40:11 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by O'Day Daniel Patrick

    4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

    3/30/26 5:59:52 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    $TUR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Gilead Sciences with a new price target

    Jefferies initiated coverage of Gilead Sciences with a rating of Buy and set a new price target of $180.00

    3/10/26 8:40:41 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Barclays initiated coverage on Gilead Sciences with a new price target

    Barclays initiated coverage of Gilead Sciences with a rating of Equal Weight and set a new price target of $155.00

    2/20/26 8:24:53 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Needham reiterated coverage on Gilead Sciences with a new price target

    Needham reiterated coverage of Gilead Sciences with a rating of Buy and set a new price target of $170.00 from $140.00 previously

    2/11/26 7:05:53 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    $TUR
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Gilead Sciences Inc.

    SCHEDULE 13G/A - GILEAD SCIENCES, INC. (0000882095) (Subject)

    3/26/26 6:40:06 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEF 14A filed by Gilead Sciences Inc.

    DEF 14A - GILEAD SCIENCES, INC. (0000882095) (Filer)

    3/20/26 4:00:50 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEFA14A filed by Gilead Sciences Inc.

    DEFA14A - GILEAD SCIENCES, INC. (0000882095) (Filer)

    3/20/26 4:01:13 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    $TUR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-6) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215973, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-8) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215974, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215973, Application Classification: Manufacturing (CMC)

    11/15/24 4:36:27 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    $TUR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026

    Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its first quarter 2026 financial results and guidance will be released on Thursday, May 7, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's first quarter 2026 financial results and provide a business update. A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The compa

    4/22/26 4:05:00 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer

    Gilead Sciences, Inc. (NASDAQ:GILD) announced today that all required regulatory approvals have been obtained for its previously announced acquisition of Arcellx and that Gilead has extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx. On April 13, 2026, the Australian Competition and Consumer Commission (ACCC) published its decision that the acquisition of Arcellx may be put into effect, subject to expiration of a 14-calendar day waiting period. Assuming that the ACCC's determination remains unchallenged during this waiting period, the waiting period expires at 10:00 a.m., Eastern Time, on April 27, 2026. Additionally, the relevant rev

    4/17/26 8:30:00 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PEPFAR and The Global Fund Make Additional Investment in Gilead's Lenacapavir for HIV Prevention to Further Expand Access

    – Additional Commitment will Expand Access to Lenacapavir to Reach Another Million People Over the Next 3 Years – Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. State Department, the United States President's Emergency Plan for AIDS Relief (PEPFAR) and The Global Fund will further invest in Gilead's twice-yearly injectable HIV prevention medicine, lenacapavir, to expand access for up to an additional 1 million people, bringing the total commitment up to 3 million people in high-incidence, resource-limited countries through 2028. Bringing together the resources and expertise of both PEPFAR and The Global Fund is a key component of Gilead's larger coordinated efforts to

    4/14/26 12:00:00 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    $TUR
    Financials

    Live finance-specific insights

    View All

    Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026

    Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its first quarter 2026 financial results and guidance will be released on Thursday, May 7, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's first quarter 2026 financial results and provide a business update. A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The compa

    4/22/26 4:05:00 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PEPFAR and The Global Fund Make Additional Investment in Gilead's Lenacapavir for HIV Prevention to Further Expand Access

    – Additional Commitment will Expand Access to Lenacapavir to Reach Another Million People Over the Next 3 Years – Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. State Department, the United States President's Emergency Plan for AIDS Relief (PEPFAR) and The Global Fund will further invest in Gilead's twice-yearly injectable HIV prevention medicine, lenacapavir, to expand access for up to an additional 1 million people, bringing the total commitment up to 3 million people in high-incidence, resource-limited countries through 2028. Bringing together the resources and expertise of both PEPFAR and The Global Fund is a key component of Gilead's larger coordinated efforts to

    4/14/26 12:00:00 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline

    – Acquisition Adds TUB-040, a NaPi2b Targeting ADC for Ovarian Cancer and other Solid Tumors, to Gilead Pipeline – – Industry Leading ADC Platform That Includes its Clinically-Validated Tubutecan Linker-Payload Technology and Next-Generation Platform to Expand Gilead's ADC Capabilities – Gilead Sciences, Inc. (NASDAQ:GILD) today announced it has entered into a definitive agreement to acquire Tubulis GmbH, a private Germany-based, clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs), building on Gilead's oncology pipeline, focused on addressing areas of high unmet need. This press release features multimedia. View the full release here: https:/

    4/7/26 8:30:00 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    $TUR
    Leadership Updates

    Live Leadership Updates

    View All

    Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance

    Gilead Sciences, Inc. (NASDAQ:GILD) announced today that Keeley Wettan will be appointed Executive Vice President, General Counsel, Legal & Compliance effective immediately. She will join the company's senior leadership team and report to Chairman and Chief Executive Officer Daniel O'Day. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218926462/en/Gilead Sciences appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance Ms. Wettan has held increasingly senior legal leadership roles within Gilead during her 14-year tenure, most recently as Senior Vice President leading the Global Legal Business Par

    12/18/25 8:30:00 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners

    DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL)., today announced the appointments of Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners. "I believe Carol and Mehrdad will be exceptional partners to the IFLI team and portfolio as they bring decades of strategic leadership and drug development expertise," said David McCullagh, Man

    10/21/25 8:05:00 AM ET
    $CRVS
    $DNA
    $EXEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

    Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company's executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affairs activities at Contineum. Dr. Watkins succeeds Stephen L. Huhn, M.D., who has been the Company's Chief Medical Officer since early 2020. Dr. Huhn will serve as an advisor during the leadership transition. "We're excited for D

    4/28/25 4:05:00 PM ET
    $CTNM
    $GILD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $GILD
    $TUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Gilead Sciences Inc. (Amendment)

    SC 13G/A - GILEAD SCIENCES, INC. (0000882095) (Subject)

    2/9/24 6:21:28 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Gilead Sciences Inc. (Amendment)

    SC 13G/A - GILEAD SCIENCES, INC. (0000882095) (Subject)

    2/13/23 3:32:27 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Gilead Sciences Inc.

    SC 13G - GILEAD SCIENCES, INC. (0000882095) (Subject)

    2/13/23 2:49:26 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care